

- or of the recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence in amino acids is represented by SEQ ID NO 2, said growth hormone being obtained by transformation of appropriate cells with the help of vectors containing a nucleotide sequence as described, recovery of the recombinant protein produced by said cells, and purification,

- or of any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2,

and preserving the property of human growth hormone of inhibiting the activation of NF- κ B.--

{Amend claim 5 as follows:}

--5. (amended) The use according to claim 1:

- of recombinant human erythropoietin such as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the help of vectors contained in a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any ~~peptide~~ sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of inhibiting the activation of NF- κ B.--

{Amend claim 6 as follows:}

--6. (amended) The use compounds inhibiting the activation of NF- κ B according to claim 1, in combination with one or several cytotoxic molecules adapted to activate the NF- κ B factor, selected from:

- cytokines,
- anthracyclines, including daunomycin, and dauxorubicin,
- vinca-alkaloids, such as vinblastine and vincristine,
- paclitaxel (or Taxel, DCI).--

a1
{Amend claim 7 as follows:}

--7. (amended) The use of compounds inhibiting the activation of NF- κ B according to claim 1, characterized in that the dosage of the cytotoxic molecules used in combination with said compounds is about 2 to about 5 times less than the dosage of these same molecules used alone in the scope of treatment of malignant hemopathies and solid tumors.--

--10. (amended) Product according to claim 8, characterized in that it comprises:

- human growth hormone, such as obtained by the extraction from hypophysary extracts, and purification,

a2
- or recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human growth hormone whose amino acid sequence is represented by SEQ ID NO 2, said growth hormone being obtained by a transformation of suitable cells with the help of vectors containing a

nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2, and keeping the property of the human growth hormone of inhibiting the activation of NF- κ B.--

Amend claim 11 as follows:

--11. (amended) Product according to claim 8, characterized in that it comprises:

- recombinant human erythropoietin as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of suitable cells with the help of vectors containing a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and keeping the property of human erythropoietin of inhibiting the activation of NF- κ B.--

Amend claim 12 as follows:

--12. (amended) Product according to claim 8, characterized in that it comprises as cytotoxic molecule susceptible of activating the NF- κ B factor, any molecule selected from the following: